Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Abemaciclib + Tamoxifen & Breast Cancer / Mammacarcinoma (HR+ Her2-), an FDA approval for abemaciclib + tamoxifen in Breast Cancer / Mammacarcinoma (HR+ Her2-) exists, but only in the adjuvant, node‑positive, high‑risk early‑breast‑cancer setting (1, 2).
EMA approves abemaciclib + tamoxifen in Breast Cancer / Mammacarcinoma (HR+ Her2-), but only in the adjuvant, node‑positive, high‑risk early‑breast‑cancer setting, as part of the broader “abemaciclib + endocrine therapy” wording (3).
(1) [FDA…